Skip to main content
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.

The genetic underpinnings of severe staph infections

A mutated gene may explain why some Staphylococcus aureus infections turn lethal, a finding with significant implications for people living with 5p- syndrome.

Titia de Lange elected to the Royal Society

She receives the honor for elucidating mechanisms of telomere protection and genome maintenance.

>

Antibody therapy controls HIV for months in new clinical trial

Unlike conventional antiretroviral drugs, treatment with broadly neutralizing antibodies does not rely on vigilant daily dosing and could potentially reduce the body’s reservoir of latent viruses.

Shixin Liu, expert in single-molecule studies of biological machines, is promoted to associate professor

Liu’s pioneering research on nano-scale molecular events is furthering our knowledge of how DNA replication and gene expression are regulated.

Kivanç Birsoy, expert on cancer cell metabolism, is promoted to associate professor 

Birsoy's groundbreaking research has highlighted key nutrients that cancer cells need to survive, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.

Richard P. Lifton to be honored with 2023 Kober Medal

Lifton, who pioneered the use of genomics to identify the basis for diseases, is recognized for a lifetime of contributions in science and mentorship.

How a narrow-spectrum antibiotic takes aim at C. diff

A new study reveals how the drug fidaxomicin selectively targets a dangerous pathogen without causing harm to beneficial bacteria. The findings could inform the development of new narrow-spectrum antibiotics for treating other types of infection.

The human genome is, at long last, complete

Even after 20 years of upgrades, eight percent of the human genome was still left unsequenced and unstudied. Until now.

The Board of Trustees has eight new members

With a breadth and depth of experience across academia, the pharmaceutical industry, technology, healthcare, and the financial sector, this latest cohort of trustees brings new skill sets and perspectives to the community.

How bacteria "self-vaccinate" against viral invaders

In studying how bacteria respond to viral infection, scientists are learning that their defense strategies cooperate in ways reminiscent of the elaborate immune systems of animals.